Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Corbaux P, Freyer G, Glehen O, You B, Bakrin N, Gelot A, Dayde D, Sajous C, Piffoux M, Peron J, Lescuyer G, Payen L, Kepenekian V. Corbaux P, et al. Among authors: payen l. Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507. Online ahead of print. Clin Cancer Res. 2024. PMID: 38819408
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms.
Gerard L, Patte C, Chardon L, Hervieu V, Payen L, Allio M, Marx C, Clermidy H, Durand A, Mehlen P, Bollard J, Poncet G, Roche C, Gibert B, Walter T. Gerard L, et al. Among authors: payen l. Endocr Relat Cancer. 2024 May 10;31(6):e240052. doi: 10.1530/ERC-24-0052. Print 2024 Jun 1. Endocr Relat Cancer. 2024. PMID: 38642579
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: payen l. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.
Barthelemy D, Lescuyer G, Geiguer F, Grolleau E, Gauthier A, Balandier J, Raffin M, Bardel C, Bouyssounouse B, Rodriguez-Lafrasse C, Couraud S, Wozny AS, Payen L. Barthelemy D, et al. Among authors: payen l. Cancers (Basel). 2023 Mar 3;15(5):1574. doi: 10.3390/cancers15051574. Cancers (Basel). 2023. PMID: 36900363 Free PMC article.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Among authors: payen l. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
104 results